Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test. The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert®. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than other stool tests.